Short Interest in Oculis Holding AG (NASDAQ:OCS) Grows By 38.8%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 34,700 shares, a growth of 38.8% from the February 28th total of 25,000 shares. Based on an average trading volume of 71,500 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.1% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on OCS shares. Chardan Capital restated a "buy" rating and set a $28.00 price objective on shares of Oculis in a research report on Thursday, March 13th. HC Wainwright lowered their price target on Oculis from $30.00 to $29.00 and set a "buy" rating on the stock in a report on Thursday, March 13th. Finally, Robert W. Baird raised their price target on Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research note on Thursday, March 13th.

Oculis Stock Performance

OCS traded down $0.71 during trading on Thursday, hitting $17.59. The company's stock had a trading volume of 36,392 shares, compared to its average volume of 46,422. The business's 50 day simple moving average is $20.31 and its 200-day simple moving average is $17.62. The firm has a market cap of $768.01 million, a PE ratio of -9.11 and a beta of 0.01. Oculis has a one year low of $10.61 and a one year high of $23.08. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

Remove Ads

Oculis (NASDAQ:OCS - Get Free Report) last announced its earnings results on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. As a group, sell-side analysts predict that Oculis will post -2.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after acquiring an additional 1,800 shares during the period. Bellevue Group AG purchased a new stake in shares of Oculis in the fourth quarter worth $170,000. Bank of America Corp DE raised its position in shares of Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after purchasing an additional 10,667 shares during the period. XTX Topco Ltd purchased a new position in shares of Oculis during the 4th quarter valued at $225,000. Finally, Citadel Advisors LLC bought a new position in Oculis in the 4th quarter worth $389,000. 22.30% of the stock is owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.